FCCC LOGO Faculty Publications
Martinez E , Tatum KL , Glass M , Bernath A , Ferris D , Reynolds P , Schnoll RA
Correlates of smoking cessation self-efficacy in a community sample of smokers
Addictive Behaviors. 2010 Feb;35(2) :175-178
PMID: ISI:000272763600019    PMCID: PMC2783543   
Back to previous list
While numerous studies show that higher levels of smoking cessation self-efficacy predicts motivation to quit smoking and successful smoking cessation, few studies have evaluated factors related to smoking cessation self-efficacy that could be targets of behavioral interventions to promote greater confidence to quit smoking. This study, using a large community sample of smokers enrolled in a smoking cessation treatment program, evaluated potential associations between self-efficacy to quit smoking and demographic (e.g., age, race), smoking-related (e.g., rate, cessation history, past use of treatments), and psychosocial (e.g., stress, cue reactivity. self-medication smoking) variables. The results indicated that Hispanic-American smokers, relative to smokers of other racial/ethnic groups, report significantly lower self-efficacy to quit smoking when facing internal stimuli (e.g., feeling depressed), as do smokers who report that they have little confidence to control abstinence-induced symptoms (F(9,576)=6.9, p<.001). The results also indicated that smokers who reported that they have little confidence to control abstinence-induced symptoms and report high smoking urge reactivity to Situations that illicit positive affect (e.g., at a bar, with coffee, at a party) report lower self-efficacy to quit smoking when facing external stimuli (e.g., during a celebration; F [7,600] = 9.05, p <.05). These findings can be used to refine behavioral smoking cessation interventions to increase self-efficacy to quit smoking. (C) 2009 Elsevier Ltd. All rights reserved.
Martinez, Elisa Tatum, Kristina L. Glass, Marcella Bernath, Albert Ferris, Daron Reynolds, Patrick Schnoll, Robert A. American Cancer Society [RSCPB-05-240-01-CPPB]; National Institutes of Health [U10 101178]; [P50 DA02585]; [R01 CA126969]; [R01 DA025078]; [R21 DA026889] This study was funded by grant RSCPB-05-240-01-CPPB to Dr.Schnoll from the American Cancer Society and National Institutes of Health grant U10 101178 to Dr. Paul Engstrom. This study was also supported in part by grants: P50 DA02585. R01 CA126969, R01 DA025078. and R21 DA026889. The funding sources had no additional role in the study. 32 Pergamon-elsevier science ltd; the boulevard, langford lane, kidlington, oxford ox5 1gb, england 532qd